



**MEMORANDUM OF UNDERSTANDING**  
**between**  
**THE DEPARTMENT OF BIOTECHNOLOGY**  
**and**  
**THE DEPARTMENT OF HEALTH RESEARCH**  
**for**  
**COLLABORATION IN AREAS OF HEALTH RESEARCH**

The Department of Biotechnology (DBT), of the Ministry of Science and Technology, Government of India and the Department of Health Research (DHR) through its autonomous agency, the Indian Council of Medical Research, Ministry of Health and Family Welfare, (hereinafter referred to as the parties);

Having recognized the importance of the cooperative efforts of health research and medical biotechnology and public health programmes.

Aware of the contribution that effective scientific and technological cooperation can make in maintaining focused efforts in collaborative research and clinical application towards enhancing the health needs of the people of the country.

The Parties have jointly agreed to:

- Set up a Joint Working Group (JWG) of experts in identified areas of mutual interest;
- Develop a policy perspective including economic analysis and forecasting for technology with potential for use in public health programmes at primary, secondary and tertiary level of health;
- Promote development of new technologies, introduction of the available technologies in the system and provide support for diffusion of the technologies into the social system. To fulfill this, joint efforts would be undertaken for product development, process optimization and scale up, product evaluation commercialization, translation and diffusion of technologies relevant to public health in India;
- Promote development of simple devices and other technologies needed for diseases affecting Indian population including vulnerable sections such as neonates, children and women;
- Identify affordable solutions to health problems of common people and to bridge the gap in technology development and promote access to these technologies for those most in need;
- Jointly build capacity in the country within the medical schools or outside the system in translational research with strong networking;
- Jointly support clinical evaluation of relevant products including design of human and animal experiments; coordinate human studies relevant to product development, research and evaluation;
- Collaborate for joint development and evaluation of vaccines, diagnostics, biomarkers, therapeutic biomolecules and nutraceuticals;

- Open their facilities and infrastructure to scientists identified under the jointly agreed programmes;
- Jointly work towards making existing technology simple and affordable;
- Coordinate translational research such as cohort and molecular ecology studies for understanding the molecular mechanism of diseases;
- Jointly support competence building through short term trainings in GLP, GCP , quality control, IPR, regulation and clinical trial skills that are critical for development of new technologies;
- Jointly support and forge partnership with industry for the development and evaluation of products for public health through Public Private Partnership;
- Jointly evolve a consensus mechanism to harmonize administrative and financial processes and approvals (evaluation, funding and monitoring) in both agencies through mutual discussion;
- Evolve a mechanism of supporting and monitoring also of jointly funded projects with Biotechnology Industry Research Assistance Council (BIRAC) and Clinical Development Services Agency(CDSA);
- All publications and other reports brought out under the aegis of this MOU shall be jointly credited to both the parties;
- All the IP rights and their costs will be shared jointly through mutual discussion;

This MOU shall come into effect on the date of its signature by both Parties and shall remain in force for a period of five years and can be renewed unless either Party terminates it by giving six month written notice.

This MOU may be modified or amended by mutual consent of the Parties. Any differences will be resolved through mutual discussions.

The termination of this MOU will not affect validity or duration of any legally binding obligations of confidentiality, ownership of IP rights or any implementing arrangements made under this MOU.

This MOU is without prejudice to co-operation being undertaken in all existing processes pursuant to other arrangements between the Parties in the field of biotechnology and health research.

IN WITNESS WHEREOF, the duly authorized Signatories of the Parties have signed this Memorandum of Understanding at New Delhi on 26<sup>th</sup> September, 2012.

*sd/-*

Dr. M.K. Bhan  
Secretary  
Department of Biotechnology  
Ministry of Science and Technology  
New Delhi

*sd/-*

Dr. V.M. Katoch  
Secretary  
Department of Health Research &  
Director General, Indian Council of Medical Research  
Ministry of Health and Family Welfare, New Delhi